Allogene Therapeutics Inc (ALLO) Receives a Hold from J.P. Morgan

By Jason Carr

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Allogene Therapeutics Inc (ALLOResearch Report) on August 7 and set a price target of $29. The company’s shares closed on Friday at $31.18.

According to, Kasimov is a 4-star analyst with an average return of 2.9% and a 44.4% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., BioMarin Pharmaceutical Inc., and ACADIA Pharmaceuticals Inc.

Allogene Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $33.

See today’s analyst top recommended stocks >>

The company has a one-year high of $35.55 and a one-year low of $21.67. Currently, Allogene Therapeutics Inc has an average volume of 459.3K.

Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.